Janssen gets EC approval for two new indications of Imbruvica

This article was originally published here

The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the

The post Janssen gets EC approval for two new indications of Imbruvica appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply